Cancer prevention and interception: A new era for chemopreventive approaches

Clinical Cancer Research

Volumn 22, Issue 17, 2016, Pages 4322-4327

  Albini, Adriana ^a   DeCensi, Andrea ^b   Cavalli, Franco ^c   Costa, Alberto ^d  

^a IRCCS MULTIMEDICA   (Italy)

^b GALLIERA HOSPITAL   (Italy)

^c ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^d EUROPEAN SCHOOL OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER INTERCEPTION; CANCER MORTALITY; CANCER PREVENTION; CANCER RESEARCH; CANCER RISK; CHEMOPROPHYLAXIS; HUMAN; LIFESTYLE MODIFICATION; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK FACTOR; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; NEOPLASM; PROCEDURES;

ANTINEOPLASTIC AGENT;

ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; HUMANS; NEOPLASMS;

EID: 84988632717     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-0695     Document Type: Article

References (45)

1. Sporn MB, Newton DL. Chemoprevention of cancer with retinoids. Fed Proc 1979;38:2528-34.
2. Albini A, Sporn MB. The tumour microenvironment as a target for chemoprevention. Nat Rev Cancer 2007;7:139-47.
3. Sporn MB. Perspective: the big C-for chemoprevention.Nature 2011;471: S10-1.
4. Blackburn EH.Cancer interception. Cancer Prev Res 2011;4:787-92.
5. Maresso KC, Tsai KY, Brown PH, Szabo E, Lippman S, Hawk ET. Molecular cancer prevention: current status and future directions. CA: Cancer J Clinic 2015;65:345-83.
6. American Association for Cancer Research. AACR Cancer Prevention Summit; 2016. Available from: http://www.aacr.org/Research/Research/ PAGES/AACR-CANCER-PREVENTION-SUMMIT.ASPX.VtbN2JMrLdd.
7. European School of Oncology. World Oncology Forum (WOF3), Prevent the Preventable. European School of Oncology; 2015. Available from: http://www.eso.net/pagine-interne/wof3.html.
8. Bonanni B, Puntoni M, Cazzaniga M, Pruneri G, Serrano D, Guerrieri-Gonzaga A, et al. Dual effect of metformin on breast cancer proliferation in a randomized presurgical trial. J Clin Oncol 2012;30:2593-600.
9. Cuzick J, Sestak I, Bonanni B, Costantino JP, Cummings S, DeCensi A, et al. Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data. Lancet 2013;381: 1827-34.
10. DeCensi A, Bonanni B, Maisonneuve P, Serrano D, Omodei U, Varricchio C, et al. A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. Ann Oncol 2013;24:2753-60.
11. Drew DA, Cao Y, Chan AT. Aspirin and colorectal cancer: the promise of precision chemoprevention. Nat Rev Cancer 2016;16:173-86.
12. Cuzick J, DeCensi A, Arun B, Brown PH, Castiglione M, Dunn B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol 2011;12:496-503.
13. Albini A, Tosetti F, Li VW, Noonan DM, Li WW. Cancer prevention by targeting angiogenesis. Nat Rev Clin Oncol 2012;9:498-509.
14. Heckman-Stoddard B, Gandini S, Puntoni M, Dunn B, DeCensi A, Szabo E. Repurposing old drugs to chemoprevention: the case of metformin. Semin Oncol 2016;43:123-33.
15. Umar A, Steele VE, Menter DG, Hawk ET. Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention. Semin Oncol 2016; 43:65-77.
16. US Preventive Service Task Force. Draft recommendation statement: aspirin to prevent cardiovascular disease and cancer. U.S. Preventive Services Task Force; 2015. Available from: http://www.uspreventiveservicestaskforce.org/Page/Document/draft-recommendation-statement/aspirin-toprevent-cardiovascular-disease-and-cancer.
17. Raimondi S, Botteri E, Munzone E, Cipolla C, Rotmensz N, DeCensi A, et al. Use of beta-blockers, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers and breast cancer survival: systematic review and meta-analysis. Int J Cancer 2016;139:212-9.
18. Talarico G, Orecchioni S, Dallaglio K, Reggiani F, Mancuso P, Calleri A, et al. Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Sci Rep 2016; 6:18673.
19. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: Cancer J Clin 2016;66:7-30.
20. Kensler TW, Spira A, Garber JE, Szabo E, Lee JJ, Dong Z, et al. Transforming cancer prevention through precision medicine and immune-oncology. Cancer Prev Res 2016;9:2-10.
21. Stewart BW, Bray F, Forman D, Ohgaki H, Straif K, Ullrich A, et al. Cancer prevention as part of precision medicine: "plenty to be done." Carcinogenesis 2016;37:2-9.
22. Rothwell PM, Fowkes FG, Belch JF, Ogawa H, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011;377:31-41.
23. Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science 2015;347:78-81.
24. Gotay C, Dummer T, Spinelli J. Cancer risk: prevention is crucial. Science 2015;347:728.
25. Potter JD, Prentice RL. Cancer risk: tumors excluded. Science 2015;347: 727.
26. Weinberg CR, Zaykin D. Is bad luck the main cause of cancer? J Natl Cancer Inst 2015;107.
27. Wild C, Brennan P, Plummer M, Bray F, Straif K, Zavadil J. Cancer risk: role of chance overstated. Science 2015;347:728.
28. Luzzatto L, Pandolfi PP. Causality and chance in the development of cancer. N Engl J Med 2015;373:84-8.
29. Albini A, Cavuto S, Apolone G, Noonan DM. Strategies to prevent "bad luck" in cancer. J Natl Cancer Inst 2015;107:djv213.
30. Giovannucci EL. Are most cancers caused by specific risk factors acting on tissues with high underlying stem cell divisions? J Natl Cancer Inst 2015;108:djv343.
31. Chan AT, Sima CS, Zauber AG, Ridker PM, Hawk ET, Bertagnolli MM. C-reactive protein and risk of colorectal adenoma according to celecoxib treatment. Cancer Prev Res 2011;4:1172-80.
32. World Health Organization. Tobacco Fact sheet N 339. World Health Organization; 2015. Available from: http://www.who.int/mediacentre/ factsheets/fs339/en/.
33. De Flora S, Ganchev G, Iltcheva M, La Maestra S, Micale RT, Steele VE, et al. Pharmacological modulation of lung carcinogenesis in smokers: preclinical and clinical evidence. Trends Pharmacol Sci 2016;37:120-42.
34. Bade B, Zdebik A, Wagenpfeil S, Graber S, Geisel J, Vogt T, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis. PLoS ONE 2014;9:e112863.
35. Kelly JL, Salles G, Goldman B, Fisher RI, Brice P, Press O, et al. Low serum vitamin D levels are associated with inferior survival in follicular lymphoma: a prospective evaluation in SWOG and LYSA studies. J Clin Oncol 2015;33:1482-90.
36. Zgaga L, Theodoratou E, Farrington SM, Din FV, Ooi LY, Glodzik D, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer. J Clin Oncol 2014;32:2430-9.
37. World Health Organization. Cancer prevention. World Health Organization; 2016. Available from: http://www.who.int/cancer/prevention/en/.
38. Millen B, Lichtenstein AH, Abrams S, Adams-Campbell L, Anderson C, Brenna JT, et al. Dietary Guidelines for Americans 2015-2020 8th edition; 2015. Available from: http://health.gov/dietaryguidelines/2015/guidelines/.
39. Iyengar NM, Hudis CA, Dannenberg AJ. Obesity and cancer: local and systemic mechanisms. Ann Rev Med 2015;66:297-309.
40. Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G. The role of the microbiota in inflammation, carcinogenesis, and cancer therapy. Eur J Immunol 2015;45:17-31.
41. Balkwill FR, Mantovani A. Cancer-related inflammation:commonthemes and therapeutic opportunities. Semin Cancer Biol 2012;22:33-40.
42. Cuzick J, Thorat MA, Bosetti C, Brown PH, Burn J, Cook NR, et al. Estimates of benefits and harms of prophylactic use of aspirin in the general population. Ann Oncol 2015;26:47-57.
43. International Agency for Research on Cancer. World Cancer Report 2014. 2014. Available from: http://publications.iarc.fr/Non-Series-Publications/ World-Cancer-Reports/World-Cancer-Report-2014.
44. Cavalli F. An appeal to world leaders: stop cancer now. Lancet 2013; 381:425-6.
45. International Agency for Research on Cancer. European Code Against Cancer. International Agency for Research on Cancer; 2015. Available from: http://cancer-code-europe.iarc.fr/index.php/en/.